The Asia-Pacific respiratory therapeutic devices marketplace is witnessing a massive surge because of the growing occurrence of respiratory issues, including chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea. The growing aging population, on the side of environmental elements, contributes to the escalating demand for respiratory therapeutic devices within the location. Ongoing technological advancements in respiratory therapeutic devices are propelling marketplace enlargement. Innovations, together with portable and person-friendly gadgets, clever inhalers, and telehealth solutions, are gaining traction, presenting patients with extra handy and powerful treatment alternatives. Growing consciousness about respiratory health and the significance of early prognosis and treatment is using marketplace increase. Educational campaigns and initiatives by means of healthcare agencies and governments are encouraging individuals to seek medical help for respiratory problems, contributing to the growing demand for healing gadgets.
As disposable incomes increase throughout the Asia-Pacific place, people are more inclined to invest in their health. This has caused a surge in healthcare spending, such as the purchase of respiratory therapeutic devices, both by individuals and healthcare institutions. High rates of smoking and deteriorating air pollution contribute to the escalating occurrence of respiration disorders. This grim truth is fueling the demand for respiratory therapeutic devices as people are searching for powerful answers to manipulate and alleviate respiration signs due to environmental elements. Market gamers are accomplishing strategic collaborations and partnerships to bolster their market presence. This consists of collaborations with healthcare carriers, studies establishments, and other stakeholders to decorate product development, distribution networks, and average market attain.
The regulatory surroundings perform a crucial role in shaping the Asia-Pacific respiratory therapeutic devices marketplace. Adherence to stringent regulatory requirements and compliance with great guarantee measures are vital for marketplace players to benefit and maintain consumer beliefs. A developing choice for domestic-primarily based healthcare answers is fostering the adoption of respiratory therapeutic devices. The Asia-Pacific vicinity is attracting global marketplace gamers seeking to capitalize on the increasing healthcare quarter. Increased market entry via global organizations brings in superior technologies and a broader range of respiratory therapeutic devices, intensifying opposition and using innovation within the market.
Report Attribute/Metric | Details |
---|---|
Growth Rate | 9.56% (2022-2030) |
Different types of respiratory therapeutic devices are present in the market. Positive airway pressure (PAP) is the most famous and widely used device in the Asia Pacific region. While high cost of the product and lack of awareness about management of respiratory diseases can hamper the growth of the market.
In April 2024, Viemed Healthcare, Inc., a player in national respiratory care and home medical products and services with technology at its heart, made announcements of the completion of its strategic alliance with East Alabama Health that gave the company ownership control over East Alabama HomeMed, LLC. HomeMed supplies home medical equipment to patients within the EAH network as well as those in surrounding areas within Eastern Alabama.
In March 2024, Medline announced that it had acquired the manufacturing rights and intellectual property for AG Cuffill from Hospitech Respiration Ltd. The device is compact and it is designed like a syringe which makes it easy to measure pressure and volume contained in airway cuffs anywhere they are used in medicine.
In February 2024, Resmed unveiled its AirCurve 11 series devices -its newest line of bilevel devices that use two levels of support (inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP)) combined with digital technology to make treatment for sleep apnea more convenient for healthcare providers while also facilitating easier patient initiation on therapy.
Zephyr® Endobronchial Valve was approved by Pulmonx Corporation on November 2022 as per their announcement release. Pulmonx Corporation, which treats severe lung diseases through minimally invasive procedures globally acknowledged Zephyr® Endobronchial Valve approval granted to them in November 2022.
July 2022: Vivos Therapeutics was granted multiple Class I clearances by the Therapeutic Goods Administration for various indications such as snoring and obstructive sleep apnoea (mild, moderate, and severe) among adults and children on several oral appliances using this concept.
July 2022: OMRON Healthcare based in Japan has introduced portable oxygen concentrator targeting home care providers managing COPD’s therapeutic & lifestyle requirements.
For instance, CAIRE launched a portable oxygen concentrator in the U.S.-LifeStyle- in June 2022 to significantly enhance the lives of patients using oxygen across America.
For instance, Max Ventilators launched multifunctional noninvasive ventilators which come with inbuild oxygen therapy and humidifier for sale in India during May 2022.
Study Objectives of Asia Pacific Respiratory Therapeutic Devices Market:
Regional Analysis
On regional basis Asia Pacific is segmented into Japan, China, India, Australia, Republic of Korea and Rest of Asia-Pacific. Increasing prevalence of diseases has increased the respiratory therapeutic device market. According to COPD foundation, it was estimated that 6.2% of total Asia Pacific population is suffering from COPD. And COPD will be the fifth leading cause for death till 2020. India has 30 million COPD patient while 8% of total china population is suffering from COPD due to increasing pollution.
Asia Pacific Respiratory Therapeutic Devices market has been segmented on the basis of-
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)